Differential long-term bivalent HPV vaccine cross-protection by variants in the Costa Rica HPV vaccine trial

Autor: Jaimie Z. Shing, Carolina Porras, Maísa Pinheiro, Rolando Herrero, Allan Hildesheim, Danping Liu, Mitchell H. Gail, Byron Romero, John T. Schiller, Michael Zúñiga, Sambit Mishra, Laurie Burdette, Kristine Jones, John Schussler, Rebeca Ocampo, Jianwen Fang, Zhiwei Liu, Douglas R. Lowy, Sabrina H. Tsang, Ana Cecilia Rodríguez, Mark Schiffman, Cameron B. Haas, Loretto J. Carvajal, Jalen R. Brown, Aimée R. Kreimer, Lisa Mirabello, Costa Rica HPV Vaccine Trial (CVT) Group
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: npj Vaccines, Vol 9, Iss 1, Pp 1-11 (2024)
Druh dokumentu: article
ISSN: 2059-0105
DOI: 10.1038/s41541-024-00896-y
Popis: Abstract The AS04-adjuvanted human papillomavirus (HPV)16/18 vaccine, an L1-based vaccine, provides strong vaccine efficacy (VE) against vaccine-targeted type infections, and partial cross-protection to phylogenetically-related types, which may be affected by variant-level heterogeneity. We compared VE against incident HPV31, 33, 35, and 45 detections between lineages and SNPs in the L1 region among 2846 HPV-vaccinated and 5465 HPV-unvaccinated women through 11-years of follow-up in the Costa Rica HPV Vaccine Trial. VE was lower against HPV31-lineage-B (VE=60.7%;95%CI = 23.4%,82.8%) compared to HPV31-lineage-A (VE=94.3%;95%CI = 83.7%,100.0%) (VE-ratio = 0.64;95%CI = 0.25,0.90). Differential VE was observed at several lineage-associated HPV31-L1-SNPs, including a nonsynonymous substitution at position 6372 on the FG-loop, an important neutralization domain. For HPV35, the only SNP-level difference was at position 5939 on the DE-loop, with significant VE against nucleotide-G (VE=65.0%;95%CI = 28.0,87.8) but not for more the common nucleotide-A (VE=7.4%;95%CI = −34.1,36.7). Because of the known heterogeneity in precancer/cancer risk across cross-protected HPV genotype variants by race and region, our results of differential variant-level AS04-adjuvanted HPV16/18 vaccine efficacy has global health implications.
Databáze: Directory of Open Access Journals